State-of-the-Art Technology and Collaboration within the Modern Health Science Ecosystem
Guildford, UK, and Burlington, Mass., October 4, 2010 – IDBS, the leading worldwide provider of data management and analytics solutions to R&D and healthcare organizations, today announced it will hold its biannual Translational and Biomarker Research Symposium on Thursday, October 14, 2010, at Altitude 360° in London. The event provides a forum for members of the pharmaceutical, biotechnology and medical research communities to network, hear real-world case studies, and share ideas on using informatics solutions and collaborative science to eliminate the barriers between scientists, data and organizations.
Translational and biomarker research studies are bringing together scientific domains and organizations, resulting in unique IT challenges in supporting the health science ecosystem. The explosion in data from genomics and image techniques, combined with the need to share diverse results and findings across organizational boundaries, is slowing the pace of innovation for many groups. The symposium will focus on how the successful collaboration between pharmaceutical and diagnostics companies, medical research institutes and hospitals is critical to improving disease understanding, treatments and patient outcomes.
- John Quackenbush, Ph.D., Professor of Computational Biology and Bioinformatics, Dana-Farber Cancer Institute
- Professor Peter Parker, Head of the Division of Cancer Studies, King’s College London, Co-Director of the King’s College London Experimental Cancer Medicine Centre and Deputy Director of the Integrated Cancer Centre
- Michael Schuitevoerder, Cancer IT Programme Director, King’s Health Partners
- Anthony Mathur, Ph.D., Professor of Cardiology & Lead for Clinical Cardiology, Barts and the London NHS Trust
- Angela Flannery, Ph.D., Lead Technologist, Stratified Medicine, The Technology Strategy Board
- Robin Munro, Ph.D., Director of Translational Medicine Solutions, IDBS
- Professor Yike Guo, Professor in Computing Science, Imperial College London
- Emanuele de Rinaldis, Sr. Research Fellow – Bioinformatics, Breakthrough Breast Research Unit, Research Oncology, Guy’s and St Thomas’ Hospital NHS Foundation Trust
- Daniel Ingber, Sr. Manager Research Information Systems, MedImmune
“IDBS is honored to be hosting such an important gathering of leading players in the health science market,” said Neil Kipling, founder and CEO of IDBS. “Our commitment and leadership position in translational medicine informatics is clearly reflected in the caliber of speakers coming together to discuss advances in the drive towards personalized medicine.”
The IDBS Translational and Biomarker Research Symposium will be held on Thursday, October 14, from 9.00am at Altitude 360° in London. For more information or to register, visit www.idbs.com/trs2010
About the IDBS Healthcare Unit
The IDBS Healthcare Unit is dedicated to the advancement of personalized medicines and improved patient outcomes through the delivery of advanced translational medicine and biomarker research informatics that bridge the worlds of clinical, molecular and image data. Our sophisticated data management and analytics solutions underpin improved disease understanding, more effective diagnosis and treatment selection. By delivering the enterprise infrastructures and managed services required for translational and biomarker studies, IDBS is revolutionizing research environments to enhance innovation, accelerate research and improve data and research quality. By working with leading organizations from bench to bedside, IDBS is enabling collaboration across the health science ecosystem.
IDBS is a unique, global supplier of innovative data management and first-in-class analytics solutions which increase efficiency reduce costs and improve the productivity of healthcare R&D organizations. Multinational pharmaceutical companies, major public-private healthcare partnerships, global leaders in academic study and high tech companies employ IDBS as a strategic supplier of scientific informatics and business process improvement solutions. IDBS is clearly differentiated by its unique combination of deep domain knowledge across the entire R&D sector: from the examination of the human genome at the scientist’s bench, through the clinic, to translational medicine initiatives and pay-for-performance healthcare monitoring. IDBS solutions support the protection of intellectual property (IP) and the requirements for data quality and security demanded under Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and HL7 (Health Level) standards.
Founded in 1989 and headquartered in Guildford, UK, IDBS has worldwide consulting and support presence, with offices in California, New Jersey and Massachusetts, as well as in the EU, Australia and China. IDBS is a 2010 Profit Track 100 company.